223 related articles for article (PubMed ID: 37173780)
1. Clinical characteristics and survival of pulmonary arterial hypertension with or without interstitial lung disease in systemic sclerosis.
Fairley JL; Hansen D; Ross L; Proudman S; Sahhar J; Ngian GS; Walker J; Host LV; Morrisroe K; Apostolopoulous D; Ferdowsi N; Wilson M; Tabesh M; Stevens W; Nikpour M;
Arthritis Res Ther; 2023 May; 25(1):77. PubMed ID: 37173780
[TBL] [Abstract][Full Text] [Related]
2. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M
Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
[TBL] [Abstract][Full Text] [Related]
4. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.
Yuan YP; Yuan P; Su YL; Jiang R; Zhang R; He J; Qiu HL; Luo CJ; Liu JM; Gong SG; Wang L; Zhao QH
Clin Rheumatol; 2022 Jun; 41(6):1675-1686. PubMed ID: 35099674
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
[TBL] [Abstract][Full Text] [Related]
6. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.
Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL
Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742
[TBL] [Abstract][Full Text] [Related]
7. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
[TBL] [Abstract][Full Text] [Related]
8. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
[TBL] [Abstract][Full Text] [Related]
9. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
Volkmann ER; Saggar R; Khanna D; Torres B; Flora A; Yoder L; Clements PJ; Elashoff RM; Ross DJ; Agrawal H; Borazan N; Furst DE; Saggar R
Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
[TBL] [Abstract][Full Text] [Related]
10. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension.
Guillén-Del-Castillo A; Meseguer ML; Fonollosa-Pla V; Giménez BS; Colunga-Argüelles D; Revilla-López E; Rubio-Rivas M; Ropero MJC; Argibay A; Barberá JA; Salas XP; Meñaca AM; Vuelta ABM; Padrón AL; Comet LS; Morera JAD; González-Echávarri C; Mombiela T; Ortego-Centeno N; González MM; Tolosa-Vilella C; Blanco I; Subías PE; Simeón-Aznar CP; ;
Sci Rep; 2022 Mar; 12(1):5289. PubMed ID: 35347225
[TBL] [Abstract][Full Text] [Related]
11. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement.
Fischer A; Kong AM; Swigris JJ; Cole AL; Raimundo K
J Rheumatol; 2018 Feb; 45(2):235-241. PubMed ID: 29142033
[TBL] [Abstract][Full Text] [Related]
12. The soluble receptor for advanced glycation end products is potentially predictive of pulmonary arterial hypertension in systemic sclerosis.
Atzeni IM; Al-Adwi Y; Doornbos-van der Meer B; Roozendaal C; Stel A; van Goor H; Gan CT; Dickinson M; Timens W; Smit AJ; Westra J; Mulder DJ
Front Immunol; 2023; 14():1189257. PubMed ID: 37409127
[TBL] [Abstract][Full Text] [Related]
13. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.
Le Pavec J; Girgis RE; Lechtzin N; Mathai SC; Launay D; Hummers LK; Zaiman A; Sitbon O; Simonneau G; Humbert M; Hassoun PM
Arthritis Rheum; 2011 Aug; 63(8):2456-64. PubMed ID: 21538327
[TBL] [Abstract][Full Text] [Related]
14. Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis.
Vandecasteele E; De Pauw M; De Keyser F; Decuman S; Deschepper E; Piette Y; Brusselle G; Smith V
Int J Cardiol; 2016 Jun; 212():265-73. PubMed ID: 27057932
[TBL] [Abstract][Full Text] [Related]
15. Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients.
Cacciapaglia F; Airò P; Fornaro M; Trerotoli P; De Lorenzis E; Corrado A; Lazzaroni MG; Natalello G; Montini F; Altomare A; Urso L; Verardi L; Bosello SL; Cantatore FP; Iannone F
Rheumatology (Oxford); 2023 Apr; 62(4):1552-1558. PubMed ID: 36074979
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease.
Trad S; Amoura Z; Beigelman C; Haroche J; Costedoat N; Boutin le TH; Cacoub P; Frances C; Wechsler B; Grenier P; Piette JC
Arthritis Rheum; 2006 Jan; 54(1):184-91. PubMed ID: 16385514
[TBL] [Abstract][Full Text] [Related]
17. A prospective, longitudinal study evaluating the baseline six-minute walk test as an individual reference value in systemic sclerosis patients.
Vandecasteele E; Melsens K; De Keyser F; De Pauw M; Deschepper E; Decuman S; Piette Y; Thevissen K; Brusselle G; Smith V
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):95-101. PubMed ID: 30183593
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome.
Alharbi S; Ahmad Z; Bookman AA; Touma Z; Sanchez-Guerrero J; Mitsakakis N; Johnson SR
J Rheumatol; 2018 Oct; 45(10):1406-1410. PubMed ID: 30008448
[TBL] [Abstract][Full Text] [Related]
19. Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.
Young A; Vummidi D; Visovatti S; Homer K; Wilhalme H; White ES; Flaherty K; McLaughlin V; Khanna D
Arthritis Rheumatol; 2019 Aug; 71(8):1339-1349. PubMed ID: 30762947
[TBL] [Abstract][Full Text] [Related]
20. Lung and gastrointestinal complications are leading causes of death in SCORE, a multi-ethnic Singapore systemic sclerosis cohort.
Santosa A; Tan CS; Teng GG; Fong W; Lim A; Law WG; Chan G; Ng SC; Low A
Scand J Rheumatol; 2016 Nov; 45(6):499-506. PubMed ID: 27232525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
